Tue, Sep 16, 2014, 10:37 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Albany Molecular Research Inc. Message Board

  • I liked the news today:
    Bristol-Myers Squibb Co. (BMY.N: Quote, Profile, Research) said on Wednesday it will spend $660 million to build a new biologics plant in the United States.

    This definitely validates Dr. D'Ambra's decision to purchase Organichem as it looks as though manufacturing pharmaceuticals in America is back in favor.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Do you know what a biologic is? AMRI's Organichem manufactures small molecules, not biologics, which are protein-based drugs such as monoclonal antibodies. How does BMS's decision to build a biologics plant have anything to do with AMRI's business strategy?

      The fact is, the outsourcing business is crushingly difficult these days. Generics are manufactured on very thin margins. AMRI doesn't have compounds in Phase III, and mentions nothing about nanotechnology in any of its press releases or analyst calls. Where do you get your "information"?

      • 1 Reply to quicktriggerfinger
      • You have to admire the spin Bashers use. �it looks as though manufacturing pharmaceuticals in America is back in favor�. That means that BMS is building a cGMP/FDA approved facility in America and not India/China�.. The logic that this is encouraging for the US industry is obvious. How can you have �sell� with the global and platform expansion underway at AMRI.

 
AMRI
21.96+0.24(+1.10%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.